← FDA DRUG APPROVALS

FDA ANDA · ANDA072164

MAPROTILINE HYDROCHLORIDE

Sponsor: WATSON LABS

APPLICATION
ANDA072164
TYPE
ANDA
ORIGINAL APPROVAL
1988-06-01
LATEST ACTION
2014-07-17
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

MAPROTILINE HYDROCHLORIDEDiscontinued
MAPROTILINE HYDROCHLORIDE 75MG · TABLET · ORAL

Approval history

2014-07-17Labeling · Supplement 10 · standardAP
2002-11-07Manufacturing (CMC) · Supplement 8AP
1999-11-10Manufacturing (CMC) · Supplement 7AP
1998-08-26Labeling · Supplement 6AP
1992-06-04Labeling · Supplement 5AP
1992-05-20Labeling · Supplement 4AP
1990-11-29Labeling · Supplement 3AP
1989-05-15Manufacturing (CMC) · Supplement 2AP
1988-06-01OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →